BioSpace News Archive

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche).

Lineage Cell Therapeutics, Inc. today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the 2023 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference , on April 25th, 2023 at 10:00 am Eastern Time.

Horizon Therapeutics plc announced the launch of the third annual global innovation challenge, The Horizon Prize, powered by MIT Solve.

Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting.

Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 3,685,000 Shares at a purchase price per Share.

SAB Biotherapeutics (Nasdaq: SABS), (SAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.

Dyadic International, Inc. today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/640,483, titled “PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA” (the “Patent”), and is expected to provide patent protection through 2038.

Rehabilitation robotics company Harmonic Bionics announced today that the company has registered their flagship exoskeleton Harmony SHR™ with the FDA as a Class II 510(k)-exempt device.

Autobahn Therapeutics today announced that it has initiated the multiple ascending dose (MAD) portion of its Phase 1 study of ABX-002 in healthy subjects.

Qualigen Therapeutics, Inc. today announces data from the Company’s four posters regarding its’ lead program, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.